Aclaris Therapeutics, Inc.

ACRS

US00461U1051

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 06/07/2024 am IST			5-day change	1st Jan Change
1.2 ^USD	+4.35%		+9.09%	+14.29%

05/07	Aclaris Therapeutics Insider Bought Shares Worth $405,894, According to a Recent SEC Filing	MT
01/07	Aclaris Therapeutics Insider Bought Shares Worth $1,742,075, According to a Recent SEC Filing	MT

Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 2500 Index

July 01, 2024

Latest news about Aclaris Therapeutics, Inc.

Aclaris Therapeutics Insider Bought Shares Worth $405,894, According to a Recent SEC Filing	06/07	MT
Aclaris Therapeutics Insider Bought Shares Worth $1,742,075, According to a Recent SEC Filing	01/07	MT
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 2000 Dynamic Index	01/07	CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell Microcap Growth Index	01/07	CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 3000E Growth Index	01/07	CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 3000E Index	01/07	CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 2500 Growth Index	01/07	CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Microcap Value Index	01/07	CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 3000 Growth Index	01/07	CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell Small Cap Comp Growth Index	01/07	CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell Small Cap Completeness Index	01/07	CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 2000 Growth Index	01/07	CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 2500 Index	01/07	CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell 3000E Value Index	01/07	CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 3000 Index	01/07	CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 2000 Index	01/07	CI
Transcript : Aclaris Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 11:20 AM	11/06
Transcript : Aclaris Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024	08/05
Earnings Flash (ACRS) ACLARIS THERAPEUTICS Reports Q1 Revenue $2.4M, vs. Street Est of $2M	08/05	MT
Aclaris Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Aclaris Therapeutics, Inc. Announces Board Resignations	20/03	CI
Aclaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02	CI
Aclaris Therapeutics, Inc. Announces Intangible Asset Impairment for the Three Months Ended December 31, 2023	27/02	CI
Earnings Flash (ACRS) ACLARIS THERAPEUTICS Posts Q4 Revenue $17.6M	27/02	MT
Aclaris Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02	CI

Chart Aclaris Therapeutics, Inc.

Duration

Period

More charts

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Aclaris Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.2 USD

Average target price

1.84 USD

Spread / Average Target

+53.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ACLARIS THERAPEUTICS, INC.	+14.29%	85.52M
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+41.98%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research